Welcome to the Villeneuve Lab
The Villeneuve Lab is interested in how the brain ages with a specific focus on the factors that modify the association between brain lesions and cognitive performances. Our research is motivated by the fact that more than 25% of older adults are considered cognitively normal despite the presence of beta-amyloid in their brain, a hallmark of Alzheimer’s disease. This fact suggests that other factors interact with beta-amyloid to trigger the expression of cognitive deficits in Alzheimer’s disease. It also suggests that actions can be taken to prevent or postpone the expression of disease-related symptoms. A main focus of The Villeneuve Lab’s research is therefore to examine the factors that protect (or worsen) the development of cognitive deficits in age-related neurodegenerative diseases. We use a multi-tier approach that includes molecular PET imaging, MRI imaging, neuropsychological testing and genetics.
Visit our research page to learn more about our ongoing projects.
If not tau pathology, then what is the cause of Suspected Non-Alzheimer disease Pathophysiology?
Villeneuve S. JAMA Neurology. 2016.
Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.
Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, DeCarli C, Seeley WW, Jagust W. Brain. 2015.
Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment.
Villeneuve S, Jagust WJ. J Prev Alzheimers Dis. 2015.
Our work is currently supported by a Canada Research Chair, the Canada Foundation for Innovation, the Alzheimer’s Society of Canada, the Alzheimer’s Association, Brain Canada, and the Canadian Institutes of Health Research.